Clinical Trials
14 trialsNCT05920356 2026-06-04
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen
Phase 3 Recruiting
NCT06333951 2026-05-28
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Amgen
Phase 1 Active not recruiting
NCT07563738 2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2 Recruiting
NCT06497556 2026-04-20
Krascendo 1
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04892017 2026-04-08
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1 Terminated
NCT07143513 2026-04-07
Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
Amgen
Completed
NCT05074810 2026-01-12
RAMP203
Verastem, Inc.
Phase 1/2 Active not recruiting
NCT05054725 2026-01-06
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Phase 2 Completed
NCT04933695 2025-10-22
CodeBreaK201
Amgen
Phase 2 Completed
NCT04667234 2025-08-13
Expanded Access of Sotorasib
Amgen
No longer available
NCT05374538 2025-05-01
VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Vitrac Therapeutics, LLC
Phase 1 Terminated
NCT05480865 2024-12-12
Argonaut
Navire Pharma Inc., a BridgeBio company
Phase 1 Terminated
NCT05180422 2023-10-18
A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
Criterium, Inc.
Phase 1/2 Withdrawn
NCT04959981 2023-07-25
HERKULES-2
Erasca, Inc.
Phase 1 Completed